Getting to a defensible Phase 1/2 plan
How an early-stage oncology biotech used AIRA to design a regulator-ready Phase 1/2 protocol - without in-house regulatory expertise and without losing months to scattered review cycles.
The team needed a regulator-ready Phase 1/2 strategy - especially around Phase 1 endpoints and escalation/expansion logic - without in-house regulatory expertise, with a lean team, and without losing weeks or months to scattered review cycles.
Three compounding risks with no easy resolution
- Endpoint uncertainty (Phase 1): Selecting primary and exploratory endpoints that would credibly support early activity signals while remaining feasible and aligned with regulatory expectations.
- Design uncertainty (Phase 1/2): Evaluating Phase 1/2 design choices without clear visibility into downstream implications - eligibility, recruitment feasibility, operational burden, interpretability.
- Regulatory defensibility risk: No in-house regulatory expertise, plus concern about whether alternative options were justifiable under regulator expectations and best practices.
- Coordination overload: Hundreds of scattered comments, Zoom notes, and cross-functional threads made it difficult to maintain a single, consistent rationale.
- Amendment risk: If nothing changed, the team expected prolonged review cycles and a high risk of protocol amendments later in development (typical average ~3.3 for comparable studies).
The familiar - and costly - workflow
- Weeks to produce the protocol draft through manual drafting and handoffs
- Hundreds of expert hours spent researching precedents and reconciling competing feedback (roughly 1.5 dedicated internal FTEs plus hundreds of external expert hours)
- Slow feedback loops - waiting weeks for expert review, restarting cycles as new concerns emerged
- Rationale drift - decisions living in comments and meeting notes, not in a unified, traceable study narrative
The result: a costly process with growing misalignment risk as the protocol evolved.
Four integrated ways the team used AIRA
AIRA as a thought partner: structured Phase 1 endpoint selection
AIRA pulled together options for Phase 1 primary and exploratory endpoints - including rationale, trade-offs, implications, patient population and eligibility impacts, and feasibility considerations tied to operational burden. AIRA also suggested an additional exploratory endpoint the team had not considered, positioned to strengthen early efficacy/activity signals while supporting a regulator-facing rationale.
AIRA AI authoring: protocol drafting grounded in full context
Based on the evolving Phase 1/2 plan and uploaded materials, AIRA drafted protocol sections aligned to the study's logic - reducing time spent translating decisions into formal protocol language and helping keep sections consistent as assumptions changed.
"AIRA at the table": proactive synthesis across scattered inputs
AIRA recognized the team's uncertainty about the Phase 2 portion across inline comments, an uploaded Zoom note, and working drafts. It suggested an adaptive design approach for the Phase 2 strategy - with a clear regulator-facing rationale and concrete implications for sample size logic and expansion decisions. Once aligned, AIRA explained cascading effects across the protocol, identified where the team needed to make decisions vs. where updates could be safely drafted, and proposed edits with connected evidence and version-aware tracking.
AIRA review: preventing feasibility and guideline misalignment
During review, AIRA flagged an unnecessarily restrictive exclusion criterion that conflicted with guideline expectations and was associated with frequent changes in comparable studies - helping reduce downstream amendment risk.
Measured across four dimensions
Quantitative
- Hundreds of internal and external expert hours saved
- Protocol first draft completed in 1 week; evolved draft in 8 weeks
- Reduced dependence on repeated external review cycles for foundational questions
Decision Quality
- More defensible Phase 1 endpoint strategy with explicit trade-offs and rationale
- Better visibility into downstream implications of Phase 1/2 design choices
- Full evidence trail, justification, and tracked changes throughout
Operational
- Faster convergence across functions despite high volumes of feedback
- Fewer stalled cycles - reconciliation in 1.5 weeks instead of a month
- No rationale loss across comments, meetings, and drafts
- Reduced duplicated operational components and SoA complexity vs. running separate protocols
- Reduced review cycles and eliminated scattered 'source-of-truth' confusion
- Lowered risk of early execution-driven amendments during site activation and enrollment
Strategic
- Improved readiness for Pre-IND discussions through clearer, consistent justification
- Lower risk of avoidable amendments by catching feasibility and compliance issues early
- Improved regulatory coherence of the Phase 1 clinical pharmacology package
- Accelerated readiness for Phase III initiation
- Reduced risk of regulator-driven clarification amendments following initial review
AIRA's most valuable contribution was not only about drafting faster and saving expert hours from tedious work - it was surfacing a better path at the moment the team was stuck.
By detecting uncertainty across scattered inputs, AIRA proposed a Phase 2 strategy alternative, explained why it was defensible, and guided the team through cascading protocol implications - turning an ambiguous debate into a regulator-ready plan.
AIRA felt like having experienced clinical and regulatory expertise in the room 24/7 - helping us compare options, understand downstream impact, and keep the protocol consistent as decisions evolved - which happened many times, and AIRA was always proactive in suggesting next steps and providing insights.
- Scientific Strategy Lead, U.S. Biotech (anonymized)
Highlighted Outcomes
- Faster convergence on Phase 1 endpoints and early activity strategy
- More defensible rationale with fewer fragmented review cycles
- Earlier detection of feasibility and guideline risks before they became amendments
Get Started
Ready to see AIRA in action?
Speak with our team to see how AIRA can support your clinical development program.
Speak with an expert